Clinical trials: Blood Plasma Therapy
Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory…
- Trial name
- NCT03314181
- Testing
- Dexamethasone, Daratumumab, Venetoclax
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Focal Segmental Glomerulosclerosis, Guillain-Barre Syndrome
Regional Citrate Anticoagulation in Plasma Exchange Treatment
The investigators want to compare the efficacy of plasma exchange treatment with using two different citrates ( 4% and 15% ) as anticoagulants in plasma exchange treatment.
- Trial name
- NCT01370200
- Testing
- plasma exchange treatment
- Where
- Slovenia
- Volunteers
- 140 people
- Sponsor
- University Medical Centre Ljubljana
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide…
- Trial name
- NCT02334865
- Testing
- Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
To explore the safety and efficacy of nanobody-based BCMA-targeting biepitope CAR-T cells in the treatment of relapsed/refractory multiple myeloma，this study will be conducted in multiple study centers, with 60 patients openly…
- Trial name
- NCT06503107
- Testing
- Nanobody-based biepitope BCMA-targeting CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells.
- Trial name
- NCT00003163
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT01801436
- Testing
- Bortezomib
- Volunteers
- 14 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infection
Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection
The investigators have previously described a limited group of HIV-1-infected patients, we called HIV controllers (HIC), who have been infected for more than 10 years, in whom viral replication is spontaneously controlled without…
- Trial name
- ANRS CO18 (NCT01065207)
- Testing
- blood test at day one
- Where
- France
- Volunteers
- 250 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Clotting Disorder Due to Plasma Exchange Therapy, Humoral Rejection After Kidney Transplantation
Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange
Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation.
- Trial name
- NCT02095821
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Hannover Medical School
COVID19, Coronavirus Infection
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements.
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases
- Trial name
- NCT04376034
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- West Virginia University
Fatigue, Acute Illness
Cohort of Repeat Donor Experiences (CORE) Study
The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the…
- Conditions
- Fatigue, Acute Illness, Self-rated Health, Health Effects (Ferritin Levels, CRP Levels, iGg Levels)
- Trial name
- CORE (NCT07543965)
- Testing
- Plasmapheresis Procedure
- Where
- 12 sites in United States
- Volunteers
- 2,400 people
- Sponsor
- Westat
Severe COVID-19 Disease
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease
Currently, there is no specific treatment or vaccine for SARS-CoV-2 available, some drugs are being investigated as treatment, but the effect is unknown.
- Trial name
- PC-COVID-HCM (NCT04542967)
- Testing
- Biological
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Hospital Central Militar
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
COVID-19
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinical efficacy and safety of…
- Trial name
- NCT04521309
- Testing
- SARS-CoV-2 antibody based IVIG therapy
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Dow University of Health Sciences
Multiple Myeloma, Myeloma-Associated Amyloidosis
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
This phase II clinical trial studies the addition of selinexor to lenalidomide in patients with multiple myeloma following transplant.
- Trial name
- NCT05820763
- Testing
- Selinexor, Lenalidomide, Dexamethasone
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and…
- Trial name
- NCT01324947
- Testing
- pomalidomide
- Where
- 91 sites in Australia, Belgium and 13 more
- Volunteers
- 74 people
- Sponsor
- Celgene
Chronic Hepatitis C
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.
- Trial name
- NCT00209755
- Testing
- therapeutic drug monitoring of ribavirin and dose adaptation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital A Michallon
Multiple Myeloma
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
The purpose of this study is to provide bortezomib to patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory or have relapse after their last treatment.
- Trial name
- NCT00440635
- Testing
- Bortezomib, tradename Velcade
- Volunteers
- 641 people
- Sponsor
- Janssen-Cilag International NV
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia, Lymphoma
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support
Open label palifermin will be administered to subjects who are at a risk of developing mucositis after radiotherapy and chemotherapy followed by blood stem cell support.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00070616
- Testing
- Palifermin 6 x 60 μg/kg/day, Palifermin 2 x 180 μg/kg/day, radiotherapy
- Volunteers
- 25 people
- Sponsor
- Swedish Orphan Biovitrum
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.